immunotherapy with antiangiogenics in nsclc
Published 6 years ago • 243 plays • Length 9:41Download video MP4
Download video MP3
Similar videos
-
3:05
rationale behind antiangiogenic therapy in nsclc
-
2:18
dr. wakelee on first trial to combine antiangiogenesis agents with immunotherapy in nsclc
-
9:12
the current role for antiangiogenic therapy for nsclc
-
1:59
dr. herbst on key immunotherapy findings in nsclc
-
1:18
dr. natale on the evolution of immunotherapy in nsclc
-
1:00
chemotherapy and immunotherapy combinations are the future of nsclc treatment
-
3:56
antiangiogenic antibodies vs tkis in nsclc
-
3:00
nsclc: mechanisms of resistance to antiangiogenic therapy
-
5:43
antiangiogenic therapy in advanced nsclc
-
2:07
using antiangiogenic therapy in nsclc in the future
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
3:55
sequencing and combining therapies with antiangiogenic monoclonal antibodies
-
4:37
immunotherapy in early stage nsclc
-
6:01
future directions for antiangiogenic therapy in lung cancer
-
5:29
resistance to antiangiogenic therapy in lung cancer
-
2:34
the future of immunotherapy in nsclc
-
1:11
dr. borghaei on immunotherapy versus chemotherapy and immunotherapy in nsclc
-
3:02
using antiangiogenic therapy in stage 4 nsclc
-
3:30
immunotherapy in locally advanced nsclc